BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway

Gu,Yue; Li,Aifang; Sun,Hui; Li,Xueru; Zha,He; Zhao,Jiali; Xie,Jiaqing; Zeng,Zongyue; Zhou,Lan

doi:10.3892/ijmm.2018.3451

BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway

Authors:
- Yue Gu
- Aifang Li
- Hui Sun
- Xueru Li
- He Zha
- Jiali Zhao
- Jiaqing Xie
- Zongyue Zeng
- Lan Zhou
View Affiliations

Affiliations: Key Laboratory of Diagnostic Medicine Designated by The Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: February 1, 2018 https://doi.org/10.3892/ijmm.2018.3451
Pages: 2660-2668
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B‑cell CLL/lymphoma 6 member B (BCL6B), a BCL6‑homologous gene, has been reported to be a tumor suppressor that is silenced in a variety of human cancers, including colorectal cancer (CRC). Although it was recently demonstrated that reduced expression of BCL6B is associated with tumor stage and lymph node metastasis in CRC, little is known on whether BCL6B contributes to CRC development, or the related underlying mechanism. The aim of the present study was to detect BCL6B expression in CRC cells, and determine the molecular mechanisms underlying the role of BCL6B in CRC development by investigating cell proliferation and migration in vitro. As a result, BCL6B expression was found to be notably repressed in CRC cells compared with normal intestinal epithelial cells by reverse transcription‑polymerase chain reaction and western blot analysis. CRC cell proliferation was significantly inhibited by BCL6B upregulation, as indicated by MTT and colony‑forming assays. Cell apoptosis was markedly induced, as indicated by flow cytometry, and BCL6B‑transfected CRC cells exhibited decreased migration ability. Additionally, BCL6B overexpression diminished the phosphorylation level of AKT in CRC cells. These effects of BCL6B were empowered by treatment with the specific phosphoinositide 3 kinase (PI3K)/AKT inhibitor LY294002. Furthermore, overexpression of BCL6B resulted in upregulation of E‑cadherin and downregulation of cyclin D1 and matrix metalloproteinase‑9, which were strongly enhanced by LY294002. In conclusion, the findings of the present study demonstrated that BCL6B suppressed the proliferation and migration of CRC cells indirectly, via inhibition of PI3K.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2010. CA Cancer J Clin. 61:10–29. 2011.
2	Meyerhardt JA, Li L, Sanoff HK, Carpenter W IV and Schrag D: Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 30:608–615. 2012. View Article : Google Scholar : PubMed/NCBI
3	Okabe S, Fukuda T, Ishibashi K, Kojima S, Okada S, Hatano M, Ebara M, Saisho H and Tokuhisa T: BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor. Mol Cell Biol. 18:4235–4244. 1998. View Article : Google Scholar : PubMed/NCBI
4	Sakashita C, Fukuda T, Okabe S, Kobayashi H, Hirosawa S, Tokuhisa T, Miyasaka N, Miura O and Miki T: Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene. Biochem Biophys Res Commun. 291:567–573. 2002. View Article : Google Scholar : PubMed/NCBI
5	Oatley JM, Avarbock MR, Telaranta AI, Fearon DT and Brinster RL: Identifying genes important for spermatogonial stem cell self-renewal and survival. Proc Natl Acad Sci USA. 103:9524–9529. 2006. View Article : Google Scholar : PubMed/NCBI
6	Manders PM, Hunter PJ, Telaranta AI, Carr JM, Marshall JL, Carrasco M, Murakami Y, Palmowski MJ, Cerundolo V, Kaech SM, et al: BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proc Natl Acad Sci USA. 102:7418–7425. 2005. View Article : Google Scholar : PubMed/NCBI
7	Zhang H, Okada S, Hatano M, Okabe S and Tokuhisa T: A new functional domain of Bcl6 family that recruits histone deacetylases. Biochim Biophys Acta. 1540:188–200. 2001. View Article : Google Scholar : PubMed/NCBI
8	Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R and Tao Q: The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res. 11:6442–6449. 2005. View Article : Google Scholar : PubMed/NCBI
9	Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC and Zent CS: Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol. 163:326–333. 2013. View Article : Google Scholar : PubMed/NCBI
10	Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q, Jin H, Zeng Z, Sung JJ and Yu J: Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut. 61:977–985. 2012. View Article : Google Scholar
11	Yang Q, Gao J, Xu L, Zeng Z, Sung JJ and Yu J: Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer. Biomarkers. 18:721–725. 2013. View Article : Google Scholar : PubMed/NCBI
12	Deng J, Han L, Dong Q, Hou Y, Xie X, Yu J, Fan D and Hao X: The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter. Open Biol. 4:1400672014. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Dong L, Xu L, Chu ES, Chen Y, Shen J, Li X, Wong CC, Sung JJ and Yu J: B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice. Cancer Lett. 355:192–200. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P and Guo M: Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. Oncotarget. 6:11547–11560. 2015.PubMed/NCBI
15	Hu S, Cao B, Zhang M, Linghu E, Zhan Q, Brock MV, Herman JG, Mao G and Guo M: Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling. Am J Cancer Res. 5:651–662. 2015.PubMed/NCBI
16	Franke TF: PI3K/Akt: Getting it right matters. Oncogene. 27:6473–6488. 2008. View Article : Google Scholar : PubMed/NCBI
17	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
18	Michl P and Downward J: Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol. 43:1133–1139. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K and Yamada O: The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 9:550–559. 2009. View Article : Google Scholar : PubMed/NCBI
20	Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar
21	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
22	Rychahou PG, Jackson LN, Silva SR, Rajaraman S and Evers BM: Targeted molecular therapy of the PI3K pathway: Therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg. 243:833–844. 2006. View Article : Google Scholar : PubMed/NCBI
23	Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003. View Article : Google Scholar : PubMed/NCBI
24	Song G, Ouyang G and Bao S: The activation of AKT/PKB signaling pathway and cell survival. J Cell Mol Med. 9:592005. View Article : Google Scholar : PubMed/NCBI
25	Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu Z, Gu Q, Liu B and Yan M: CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway. Plos One. 9:e1129082014. View Article : Google Scholar : PubMed/NCBI
26	Ptak A, Hoffmann M, Gruca I and Barć J: Bisphenol A induce ovarian cancer cell migration via the MAPK and PI3K/Akt signalling pathways. Toxicol Lett. 229:357–365. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, et al: Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 68:2764–2772. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ying J, Poon F, Yu J, Geng H, Wong AH, Qiu GH, Goh HK, Rha SY, Tian L, Chan AT, et al: DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 100:663–669. 2009. View Article : Google Scholar : PubMed/NCBI
29	Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, et al: Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer. 12:662012. View Article : Google Scholar : PubMed/NCBI
30	Migheli F and Migliore L: Epigenetics of colorectal cancer. Clin Genet. 81:312–318. 2012. View Article : Google Scholar : PubMed/NCBI
31	Conacci-Sorrell M, Zhurinsky J and Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 109:987–991. 2002. View Article : Google Scholar : PubMed/NCBI
32	Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, et al: Colorectal cancer: Mutations in a signalling pathway. Nature. 436:7922005. View Article : Google Scholar : PubMed/NCBI
33	Burgering BM and Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376:599–602. 1995. View Article : Google Scholar : PubMed/NCBI
34	Ekstrand AI, Jönsson M, Lindblom A, Borg Å and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 9:125–129. 2010. View Article : Google Scholar
35	Lau MT and Leung PC: The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
36	Dilly AK, Ekambaram P, Guo Y, Cai Y, Tucker SC, Fridman R, Kandouz M and Honn KV: Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. Int J Cancer. 133:1784–1791. 2013. View Article : Google Scholar : PubMed/NCBI